Earnings summaries and quarterly performance for BIO-RAD LABORATORIES.
Executive leadership at BIO-RAD LABORATORIES.
Norman Schwartz
Detailed
Chief Executive Officer
CEO
CC
Colleen Corey
Detailed
Executive Vice President, Global Human Resources
CE
Courtney Enloe
Detailed
Executive Vice President, General Counsel and Secretary
EE
Eva Engelhardt
Detailed
Executive Vice President and President, Clinical Diagnostics Group
JB
James Barry
Detailed
Executive Vice President and President, Life Science Group
JD
Jonathan DiVincenzo
Detailed
President and Chief Operating Officer
RM
Rajat Mehta
Detailed
Executive Vice President, Global Commercial Operations
RL
Roop Lakkaraju
Detailed
Executive Vice President, Chief Financial Officer
SE
Sedat Evran
Detailed
Executive Vice President, Global Supply Chain
Board of directors at BIO-RAD LABORATORIES.
Research analysts who have asked questions during BIO-RAD LABORATORIES earnings calls.
Jack Meehan
Nephron Research LLC
6 questions for BIO
Also covers: A, AVTR, CARS +18 more
Tycho Peterson
Jefferies
5 questions for BIO
Also covers: A, AVTR, BLLN +22 more
Brandon Couillard
Wells Fargo & Company
4 questions for BIO
Also covers: A, AVTR, BRKR +10 more
DL
Dan Leonard
UBS Group AG
3 questions for BIO
Also covers: A, AVTR, DHR +13 more
CN
Conor Noel McNamara
RBC Capital Markets
2 questions for BIO
Also covers: AVTR, HOLX, ILMN +6 more
DL
Daniel Leonard
Stifel Financial Corp.
2 questions for BIO
Also covers: A, AVTR, CRL +15 more
Patrick Donnelly
Citi
2 questions for BIO
Also covers: A, AVTR, BRKR +24 more
DC
David Carter
RBC Capital Markets
1 question for BIO
MT
Matt Taylor
Jefferies & Company Inc.
1 question for BIO
Also covers: ABT, BAX, BDX +16 more
Recent press releases and 8-K filings for BIO.
BIO-RAD LABORATORIES Reports Q4 and Full-Year 2025 Results
BIO
Earnings
Guidance Update
Share Buyback
- BIO-RAD LABORATORIES reported Q4 2025 Non-GAAP revenue of $693 million, a 3.9% year-over-year increase, with a Non-GAAP gross margin of 52.5% and Non-GAAP operating margin of 12.0%. For the full year 2025, Non-GAAP revenue was $2,583 million, up 0.7% year-over-year, with Non-GAAP gross margin at 53.3% and Non-GAAP operating margin at 12.1%.
- In 2025, the company generated $532 million in cash from operations and $375 million in free cash flow, deploying $296 million for share repurchases.
- Segment performance in Q4 2025 saw the Life Science Group revenue decline by 2.6% year-over-year to $268 million due to constrained academic research and biotech funding, while the Clinical Diagnostics Group revenue grew by 8.4% year-over-year to $425 million, driven by growth in quality controls, blood typing, and diabetes products.
- For Full-Year 2026, BIO-RAD LABORATORIES projects currency neutral revenue growth of 0.5% to +1.5%, Non-GAAP gross margin of 54.0% to 54.5%, and Non-GAAP operating margin of 12.0% to 12.5%.
Feb 12, 2026, 10:00 PM
Bio-Rad Laboratories Reports Q4 and Full-Year 2025 Results and Provides 2026 Outlook
BIO
Earnings
Guidance Update
Share Buyback
- Bio-Rad Laboratories announced its Q4 and full-year 2025 financial results :
| Metric | Q4 2025 | FY 2025 |
|---|---|---|
| Net Sales ($USD Millions) | $693 | $2,583 |
| Net Sales (Currency Neutral % Change YoY) | 1.7% | Essentially flat |
| Non-GAAP Gross Margin (%) | 52.5% | 53.3% |
| Non-GAAP Operating Margin (%) | 12% | 12.1% |
| Non-GAAP Diluted EPS ($USD) | $2.51 | $9.92 |
| Free Cash Flow ($USD Millions) | $119 | $375 |
- The Clinical Diagnostics segment returned to growth, increasing 5.6% currency neutral in Q4 2025, driven by quality control and blood typing products. Conversely, the Life Science segment saw a 4% currency neutral decline in Q4 due to constrained academic research and biotech funding, although the ddPCR portfolio achieved mid-single-digit growth.
- The company also provided its full-year 2026 guidance :
| Metric | FY 2026 Guidance |
|---|---|
| Currency Neutral Revenue Growth (%) | 0.5% - 1.5% |
| Non-GAAP Gross Margin (%) | 54% - 54.5% |
| Non-GAAP Operating Margin (%) | 12% - 12.5% |
| Free Cash Flow ($USD Millions) | $375 - $395 |
- This guidance reflects a projected mid-teens decline in the Process Chromatography business for 2026. In 2025, Bio-Rad retired 1.2 million shares through buybacks totaling $296 million and is actively assessing additional M&A opportunities.
Feb 12, 2026, 10:00 PM
Bio-Rad Laboratories Reports Q4 and Full Year 2025 Results and Provides 2026 Guidance
BIO
Earnings
Guidance Update
Demand Weakening
- Bio-Rad Laboratories reported Q4 2025 net sales of $693 million, a 1.7% currency-neutral increase year-over-year, while non-GAAP diluted EPS decreased to $2.51 from $2.90 in Q4 2024. For the full year 2025, net sales were $2.583 billion, essentially flat currency-neutral, with non-GAAP diluted EPS of $9.92.
- The company recorded a GAAP operating loss of $119 million in Q4 2025, including $173 million in impairment charges from portfolio rationalization, and Q4 non-GAAP gross margin was pressured by higher supply chain costs.
- For 2026, Bio-Rad Laboratories projects full-year currency-neutral revenue growth between 0.5% and 1.5% and a non-GAAP operating margin between 12% and 12.5%. The Process Chromatography business is projected to decline approximately mid-teens in 2026 due to changing regulations and customer efficiencies.
- Key growth drivers include the Clinical Diagnostics segment, which grew 5.6% currency-neutral in Q4 2025, and the ddPCR portfolio, which posted mid-single-digit growth, boosted by the QX700 platform and the Stilla acquisition. The company generated $375 million in free cash flow for FY 2025 and repurchased 1.2 million shares for $296 million.
Feb 12, 2026, 10:00 PM
Bio-Rad Laboratories Announces Q4 and Full Year 2025 Results and 2026 Guidance
BIO
Earnings
Guidance Update
Demand Weakening
- Bio-Rad Laboratories reported Q4 2025 net sales of approximately $693 million (up 3.9% on a reported basis year-over-year) and full-year 2025 net sales of $2.583 billion (up 0.7% on a reported basis). Non-GAAP diluted EPS was $2.51 for Q4 2025 and $9.92 for full-year 2025.
- The company provided 2026 guidance, projecting currency neutral revenue growth between 0.5% and 1.5%, non-GAAP operating margin between 12% and 12.5%, and free cash flow between $375 million and $395 million.
- The Life Science segment's Process Chromatography business is projected to decline approximately mid-teens in 2026, which is expected to impact the overall operating margin by 50 basis points. Conversely, the ddPCR business is expected to grow mid-single-digit.
Feb 12, 2026, 10:00 PM
Bio-Rad Laboratories, Inc. Announces Q4 and Full-Year 2025 Financial Results
BIO
Earnings
Guidance Update
Share Buyback
- Bio-Rad Laboratories, Inc. reported Q4 2025 revenue of $693.2 million (up 3.9% year-over-year) and full-year 2025 revenue of $2,583.2 million (up 0.7% year-over-year). GAAP net income for Q4 2025 was $720.0 million ($26.65 diluted EPS) and $759.9 million ($27.85 diluted EPS) for the full year, significantly influenced by the change in fair market value of its investment in Sartorius AG.
- 2025 was a challenging year due to geopolitical uncertainty and pressure on academic research funding, which affected gross and operating margin performance. The company successfully integrated the acquisition of digital PCR developer Stilla Technologies.
- For full-year 2025, Bio-Rad generated $532 million in cash from operations and $375 million in free cash flow, and deployed $296 million for share repurchases.
- The company provided a full-year 2026 outlook, expecting non-GAAP, currency neutral revenue growth of approximately 0.5% to 1.5% and an estimated non-GAAP operating margin of approximately 12.0% to 12.5%.
Feb 12, 2026, 9:16 PM
Bio-Rad Laboratories Announces Q4 and Full-Year 2025 Financial Results and 2026 Outlook
BIO
Earnings
Guidance Update
M&A
- Bio-Rad Laboratories reported Q4 2025 revenue of $693.2 million and full-year 2025 revenue of $2,583.2 million, marking increases of 3.9% and 0.7% respectively over the prior year periods.
- The company achieved GAAP net income of $720.0 million ($26.65 per diluted share) for Q4 2025 and $759.9 million ($27.85 per diluted share) for the full-year 2025. Non-GAAP net income was $67.7 million ($2.51 per diluted share) for Q4 2025 and $270.5 million ($9.92 per diluted share) for the full-year.
- CEO Norman Schwartz described 2025 as challenging due to geopolitical uncertainty and academic research funding pressure, despite which the company delivered modest revenue growth and strong free cash flow.
- For full-year 2026, Bio-Rad expects non-GAAP, currency neutral revenue growth of approximately 0.5% to 1.5% and an estimated non-GAAP operating margin of approximately 12.0% to 12.5%.
Feb 12, 2026, 9:15 PM
Insight Molecular Diagnostics Provides Business Update, Nearing GraftAssureDx FDA Submission
BIO
Product Launch
New Projects/Investments
Guidance Update
- Insight Molecular Diagnostics (iMDx) announced its GraftAssureDx™ FDA IVD approval application is 95% complete, with full submission expected in the coming weeks.
- The company is accelerating its planned UK CE mark and EU IVDR submission for GraftAssureDx™ to the first half of 2026.
- By year-end 2025, 20 global transplant centers were engaged with iMDx's GraftAssure™ technology, including its first Canadian site.
- Seventeen U.S. transplant centers are planning to send samples to the GraftAssureCore™ kidney registry in 2026.
- iMDx targets a $1 billion-plus addressable market for kitted transplant rejection testing.
Jan 5, 2026, 12:00 PM
BIO Reports Q3 2025 Financial Results and Reaffirms Full-Year Outlook
BIO
Earnings
Guidance Update
Demand Weakening
- For Q3 2025, BIO reported GAAP revenue of $653 million, a 0.5% year-over-year increase, with a GAAP operating margin of 10.0%. Non-GAAP revenue was also $653 million, with a non-GAAP operating margin of 11.8%.
- Currency neutral revenue for Q3 2025 saw a 1.7% year-over-year decline, with both the Life Science Group and Clinical Diagnostics Group experiencing currency neutral revenue declines of 1.5% and 1.8% respectively.
- Net cash from operations for Q3 2025 was $121 million, and free cash flow was $89 million. Cash and short-term investments decreased to $1,419 million as of September 30, 2025, from $1,665 million on December 31, 2024.
- BIO is maintaining its Full-Year 2025 outlook, projecting currency neutral revenue growth of 0.0% to +1.0% and non-GAAP free cash flow between $310 million and $330 million.
Oct 29, 2025, 9:00 PM
Bio-Rad Laboratories Reports Q3 2025 Results and Maintains Full-Year Guidance
BIO
Earnings
Guidance Update
Demand Weakening
- Bio-Rad Laboratories reported Q3 2025 net sales of $653 million, a 0.5% increase on a reported basis but a 1.7% decrease currency-neutral, with non-GAAP diluted earnings per share of $2.26.
- The Life Science segment sales were flat on a reported basis, impacted by continued softness in academic research and biotech funding, while the Clinical Diagnostics segment sales increased 0.6% on a reported basis, despite lower reimbursement rates for diabetes testing in China.
- The company maintained its full-year 2025 outlook, projecting total currency-neutral revenue growth in the range of flat to 1% and a non-GAAP operating margin between 12% and 13%.
- In Q3 2025, Bio-Rad generated $89 million in free cash flow and repurchased 212,578 shares for $53 million. Management expects a modest revenue improvement in life sciences and a return to growth in diagnostics for Q4 2025.
Oct 29, 2025, 9:00 PM
Bio-Rad Reports Q3 2025 Results and Maintains Full-Year Guidance
BIO
Earnings
Guidance Update
Share Buyback
- Bio-Rad reported Q3 2025 net sales of approximately $653 million, a 0.5% increase on a reported basis but a 1.7% decrease currency-neutral, with non-GAAP diluted earnings per share of $2.26 and a non-GAAP operating margin of 11.8%.
- The Life Science segment sales were $262 million, flat on a reported basis, with strong double-digit growth in process chromatography offsetting a 6% year-over-year decrease in core Life Science revenue (excluding process chromatography) due to softness in academic research and biotech funding.
- The Clinical Diagnostics segment sales were $391 million, a 0.6% increase on a reported basis, but a 1.8% decrease currency-neutral, primarily impacted by lower reimbursement rates for diabetes testing in China.
- The company maintained its full-year 2025 outlook for total currency-neutral revenue growth of flat to 1% and non-GAAP operating margin of 12%-13%, anticipating a return to growth in Diagnostics and sequential operating margin improvement of at least 80 basis points in Q4.
- During Q3 2025, Bio-Rad repurchased 212,578 shares for $53 million, with approximately $285 million remaining under the current buyback program.
Oct 29, 2025, 9:00 PM
Quarterly earnings call transcripts for BIO-RAD LABORATORIES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more